Ascendis Pharma A (ASND) Cash from Operations (2014 - 2026)

Ascendis Pharma A has reported Cash from Operations for 13 years, with the latest figure at 9039327.16 in Q1 2026.

• Quarterly Cash from Operations rose 39.96% year-over-year to 9039327.16 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 138536135.97 (up 41.27% YoY) and the FY2025 annual result came in at 146404080.93, up 55.26% from the prior year.
• Cash from Operations improved to 9039327.16 in Q1 2026 per ASND's latest filing, from 123704068.35 in the prior quarter.
• Over five years, Cash from Operations peaked at 2516975.61 in Q3 2025 and troughed at 166744814.28 in Q2 2023.
• A 5-year average of 89090117.61 and a median of 99650776.84 in 2022 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2024 and 2025: Cash from Operations tumbled 103.86% in 2024, then soared 104.08% in 2025.
• Over 5 years, Cash from Operations stood at 144553747.95 in 2022, then soared by 68.39% to 45695167.93 in 2023, then sank by 103.86% to 93155872.6 in 2024, then sank by 32.79% to 123704068.35 in 2025, then jumped by 92.69% to 9039327.16 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 9039327.16, 123704068.35, and 2516975.61 for Q1 2026, Q4 2025, and Q3 2025 respectively.